Randomized evaluation of atorvastatin in patients with coronary heart disease - A serial intravascular ultrasound study

Circulation Journal

Volumn 71, Issue 12, 2007, Pages 1845-1850

  Yamada, Takashi ^a   Azuma, Akihiro ^a   Sasaki, Susumu ^a   Sawada, Takahisa ^a   Matsubara, Hiroaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Atorvastatin; Coronary heart disease; Intravascular ultrasound

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

AGED; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVASCULAR ULTRASOUND; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY DISEASE; CORONARY VESSELS; DISEASE PROGRESSION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 37149000413     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.71.1845     Document Type: Article

References (34)

1. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
2. Athyros VG. Papageorgiou AA, Mercouris BR, Athyrou VV. Symeonidis AN. Basayannis EO. et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention: The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002; 18: 220-228.
3. Serruys PW. de Feyter P. Macaya C, Kokott M, Puel J, Vrolix M, et al for the Lescol Intervention Prevention Study (LIPS) Investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 287: 3215-3222.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet 1994; 344: 1383-1389.
5. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
6. Shepherd J. Cobbe SM. Ford I. Isles CG, Lorimer AR, MacFarlane PW. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
7. LaRosa JC. He J. Vupputuri S. Effects of statins on risk of coronary disease: A meta analysis of randomized controlled trials. JAMA 1999; 282: 2340-2346.
8. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation. And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
9. Hata Y. Mabuchi H. Saito Y. Itakura H, Egusa G, Ito H, et al; Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9: 1-27.
10. Pearson TA. Laurora I. Chu H. Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-467.
11. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572.
12. Matsubara K. Yamamoto Y. Sonoyama K, Igawa G, Furuse M. Yatsuhashi T. et al. Current status of lipid management of hypertensive patients. Hypertens Res 2003; 26: 699-704.
13. Verschuren WM. Jacobs DR. Bloemberg BP, Kromhout D, Menotti A. Aravanis C. et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: Twenty-five-year follow-up of seven countries study. JAMA 1995; 274: 131-136.
14. Sekikawa A. Satoh T. Hayakawa T, Ueshima H, Kuller LH. Coronary heart disease mortality among men aged 35-44 years by prefecture in Japan in 1955-1999 compared with that among white men aged 35 44 by state in United States in 1995-1998: Vital statistics data in recent birth cohort. Jpn Circ J 2001; 65: 887-892.
15. Kodama K. Sasaki H. Shimizu Y. Trend of coronary heart disease and its relationship to risk factors in a Japanese population: A 26-year follow-up. Hiroshima/Nagasaki study. Jpn Circ J 1990; 54: 414-421.
16. Sacks FM. Pfeffer MA. Moye LA, Rouleau JL Rutherford JD, Cole TG. et al for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
17. Sacks FM. Tonkin AM. Shepherd J, Braunwald E, Cobbe S. Hawkins CM. et al for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project. Circulation 2000; 102: 1893-1900.
18. Cannon CP. Braunwald E. McCabe CH, Rader DJ, Rouleau JL, Belder R. et al for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-1504.
19. Schartl M. Bocksch W. Koschyk DH, Voelker W, Karsch KR. Kreuzer J. et al. Use of intravascular ultrasound to compare effects of different strategies of lipid lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104: 387-392.
20. Nissen SE. Tuzcu EM. Schoenhagen P, Brown BG, Ganz P, Vogel RA. et al: REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-1080.
21. Nissen SE. Nicholls SJ. Sipahi I, Libby P, Raichlen JS, Ballantyne CM. et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006; 295: 1556-1565.
22. Okazaki S. Yokoyama T. Miyauchi K, Shimada K, Kurata T, Sato H. et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 2004; 110: 1061-1068.
23. Blankenhorn DH. Azen SP. Kramsch DM, Mack WJ, Cashin-Hemphill L. Hodis HN. et al. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969-976.
24. MAAS investigations. Effects of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-638.
25. Jukema JW. Bruschke AV. van Boven AJ, Reiber JH, Bal ET. Zwinderman AH. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to elevated serum cholesterol levels: The Progression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-2540.
26. Yokoi H. Nobuyoshi M. Mitsudo K, Kawaguchi A, Yamamoto A: ATHEROMA Study Investigators. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 2005; 69: 875-883.
27. Mintz GS. Painter JA. Pichard AD, Kent KM, Satler LF, Popma JJ. et al. Atherosclerosis in angiographically "normal" coronary artery reference segments: An intravascular ultrasound study with clinical correlations. J Am Coll Cardiol 1995; 25: 1479-1485.
28. Sano K. Kawasaki M. Okubo M, Yokohama H, Ito Y, Murata I, et al. In vivo quantitative tissue characterization of angiographically normal coronary lesions and the relations with risk factor: A study using integrated backscatter intravascular ultrasound Circ J 2005; 69: 543-549.
29. Crisby M. Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103: 926-933.
30. Zhao XQ. Yuan C. Hatsukami TS, Frechette EH, Kang XJ, Maravilla KR. et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case-control study. Arterioscler Thromb Vasc Biol 2001; 21: 1623-1629.
31. Nakamura M. Nishikawa H. Mukai S, Setsuda M, Nakajima K. Tamada H. et al. Impact of coronary artery remodeling on clinical presentation of coronary artery disease: An intravascular ultrasound study. J Am Coll Cardiol 2001; 37: 63-69.
32. Schoenhagen P. Ziada KM. Kapadia SR, Crowe TD, Nissen SE. Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: An intravascular ultrasound study. Circulation 2000; 101: 598-603.
33. Yamagishi M. Terashima M. Awano K, Kijima M, Nakatani S. Daikoku S. et al. Morphology of vulnerable coronary plaque: Insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol 2000; 35: 106-111.
34. Corti R. Fayad ZA. Fuster V. Worthley SG, Helft G, Chesebro J, et al. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: A longitudinal study by high-resolution noninvasive magnetic resonance imaging. Circulation 2001; 104: 249-252.